Compounds having the formula (I), ##STR1##

and pharmaceutically acceptable salts or prodrugs thereof, are useful as kinase inhibitors, wherein Y is —C(O)NR1—, —NR1C(O)—, —NR1C(O)NR1—, —NR1SO2—, —SO2NR1—, —C(O)—, —OC(O)—, or —CO2—; B is alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, and heterocyclo; or when Y is —C(O)NR1—, B also may be selected from —C(O)R8, —C(O)NR8R9, and —CO2R8; R1 is hydrogen, C1-4alkyl, or substituted C1-4alkyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen, methyl, perfluoromethyl, hydroxy, methoxy, halogen, cyano, NH2, or NH(CH3); and R4, R5, R6, R7, R8, and R9 are as defined in the specification.

 
Web www.patentalert.com

< Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them

< Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds

> Substituted diamino-1,3,5-triazine derivatives

> Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating

~ 00219